Caudate and putamen volumes in good and poor outcome patients with schizophrenia

被引:80
作者
Buchsbaum, MS
Shihabuddin, L
Brickman, AM
Miozzo, R
Prikryl, R
Shaw, R
Davis, K
机构
[1] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA
[2] Bronx Vet Adm Med Ctr, Bronx, NY USA
[3] Fac Hosp Brno, Dept Psychiat, Brno, Czech Republic
关键词
caudate; putamen; Kraepelinian subtype;
D O I
10.1016/S0920-9964(02)00526-1
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Magnetic resonance images of 37 patients with schizophrenia and 37 age- and sex-matched volunteers were acquired. The caudate nucleus and putamen were traced on axial slices from the most superior extent of the caudate to the most inferior point where the caudate and putamen merge. Two subtypes of schizophrenia were compared, the Kraepelinian subtype (n = 13), characterized by an unremitting and severe course, and the non-Kraepelinian subtype (n = 24), characterized by a remitting course and some periods of self-care. Patients with good outcome schizophrenia had larger relative mean putamen size (0.0129) than poor outcome patients (0.0123) or normal controls (0.0121), but not caudate size. This enlargement was most marked for the dorsal putamen and right hemisphere. Striatal size was not related to whether patients were currently being treated with atypical or typical neuroleptics or whether they had been predominantly treated with typical or atypical neuroleptics over the past 3 years. This suggests the possibility that the expansion of putamen size may be a physiological correlate of neuroleptic responsiveness or that small putamen size at disease onset may be a predictor of outcome. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:53 / 62
页数:10
相关论文
共 31 条
[1]  
ANDREASEN NC, 1992, ARCH GEN PSYCHIAT, V49, P615
[2]   Visualizing fronto-striatal circuitry and neuroleptic effects in schizophrenia [J].
Buchsbaum, MS ;
Hazlett, EA ;
Haznedar, MM ;
Spiegel-Cohen, J ;
Wei, TC .
ACTA PSYCHIATRICA SCANDINAVICA, 1999, 99 :129-137
[3]  
BUCHSBAUM MS, 1992, NEUROPSYCHOPHARMACOL, V6, P155
[4]  
CHAKOS MH, 1994, AM J PSYCHIAT, V151, P1430
[5]  
Corson PW, 1999, AM J PSYCHIAT, V156, P1200
[6]   Ventricular enlargement in poor-outcome schizophrenia [J].
Davis, KL ;
Buchsbaum, MS ;
Shihabuddin, L ;
Spiegel-Cohen, J ;
Metzger, M ;
Frecska, E ;
Keefe, RS ;
Powchik, P .
BIOLOGICAL PSYCHIATRY, 1998, 43 (11) :783-793
[7]   Schizophrenia as a chronic active brain process: A study of progressive brain structural change subsequent to the onset of schizophrenia [J].
DeLisi, LE ;
Sakuma, M ;
Tew, W ;
Kushner, M ;
Hoff, AL ;
Grimson, R .
PSYCHIATRY RESEARCH-NEUROIMAGING, 1997, 74 (03) :129-140
[8]   6-18F-DOPA PET study in patients with schizophrenia [J].
Elkashef, AM ;
Doudet, D ;
Bryant, T ;
Cohen, RM ;
Li, SH ;
Wyatt, RJ .
PSYCHIATRY RESEARCH-NEUROIMAGING, 2000, 100 (01) :1-11
[9]   Absence of neurodegeneration in the thalamus and caudate of elderly patients with schizophrenia [J].
Falke, E ;
Han, LY ;
Arnold, SE .
PSYCHIATRY RESEARCH, 2000, 93 (02) :103-110
[10]   Atrophic and static (neurodevelopmental) schizophrenic psychoses: Premorbid functioning, symptoms and neuroleptic response [J].
Garver, DL ;
Nair, TR ;
Christensen, JD ;
Holcomb, J ;
Ramberg, J ;
Kingsbury, S .
NEUROPSYCHOPHARMACOLOGY, 1999, 21 (01) :82-92